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Abstract: Shiga toxins (Stxs) produced by Shiga toxin-producing bacteria Shigella dysenteriae serotype 1
and select serotypes of Escherichia coli are primary virulence factors in the pathogenesis of hemorrhagic
colitis progressing to potentially fatal systemic complications, such as hemolytic uremic syndrome
and central nervous system abnormalities. Current therapeutic options to treat patients infected with
toxin-producing bacteria are limited. The structures of Stxs, toxin-receptor binding, intracellular
transport and the mode of action of the toxins have been well defined. However, in the last decade,
numerous studies have demonstrated that in addition to being potent protein synthesis inhibitors,
Stxs are also multifunctional proteins capable of activating multiple cell stress signaling pathways,
which may result in apoptosis, autophagy or activation of the innate immune response. Here, we
briefly present the current understanding of Stx-activated signaling pathways and provide a concise
review of therapeutic applications to target tumors by engineering the toxins.
Keywords: Shiga toxins; Shiga toxin type 1 and 2; Shiga toxin-producing Escherichia coli; hemolytic
uremic syndrome; signaling pathways; cancer therapeutics
1. Introduction
Shiga toxin (Stx) is a protein exotoxin expressed by the Gram-negative bacteria Shigella dysenteriae
serotype 1. The toxin is named after Dr. Kiyoshi Shiga, a Japanese bacteriologist who first identified
bacteria that came to be called “Shiga’s bacillus” as the causative agent of a widespread outbreak of “red
diarrhea” (dysentery) in 1897 [1]. The work of many microbiologists in the early 20th century defined
cytotoxic, neurotoxic and enterotoxic activities in extracts prepared from the organism variously
known as Shiga’s bacillus, Bacillus dysenteriae, Shigella shigae and now classified as S. dysenteriae
serotype 1. In 1980, the publication of purification protocols for Shiga toxin from Shigella dysenteriae
serotype 1 greatly facilitated the study of the toxin [2,3]. In 1977, culture filtrates prepared from some
E. coli strains causing diarrhea in humans were shown to produce a cytotoxin capable of killing Vero
cells [4]. Based on this observation, the cytotoxin was referred to as Vero cytotoxin or Verotoxin.
Shortly thereafter, it was reported that a Shiga-like toxin was produced by E. coli O157:H7 strain 933
that had caused an outbreak of hemorrhagic colitis in the United States [5]. The toxin was capable of
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killing Vero and HeLa cells, was lethal when administered to mice and caused fluid accumulation
in ligated rabbit ileal loops. Subsequently, E. coli O157:H7 strain 933 was shown to be lysogenized
by two toxin-converting bacteriophages encoding toxins that were antigenically similar to Shiga
toxin [5]. Recently, Mora et al. [6] reported that over 470 E. coli serotypes causing disease in humans
harbor bacteriophages encoding genetic variants of Shiga toxin expressed by S. dysenteriae serotype 1.
Collectively, these E. coli are called Shiga toxin-producing E. coli (STEC) or Verotoxin-producing E. coli
(VTEC), and the terms Shiga toxins or Verotoxins are used to describe the same toxins [7].
Shigella dysenteriae serotype 1 and STEC are major public health concerns in developed and
developing countries due to the severity of the diseases they cause. Infections with S. dysenteriae
serotype 1 (shigellosis) and STEC may result in bloody diarrhea (hemorrhagic colitis) and the
subsequent development of life-threatening sequelae, including acute renal failure and neurological
abnormalities, such as seizures, paralysis, blindness and death [8]. The young and elderly are most
vulnerable to developing life-threatening complications following infection with S. dysenteriae serotype
1 or STEC [9]. The acute renal failure that may follow hemorrhagic colitis is the main feature of
hemolytic uremic syndrome (HUS). HUS is defined by a triad of symptoms: thrombocytopenia,
microangiopathic hemolytic anemia and acute renal failure. Readers are referred to several excellent
reviews on the extra-intestinal complications that may follow the ingestion of Shiga toxin-producing
bacteria [10–12]. Human-to-human transmission via the fecal-oral route is the primary mode of
transmission of S. dysenteriae serotype 1. In the environment, ruminant animals serve as reservoirs
for STEC, with the primary mode of transmission to humans mainly involving fecal contamination of
drinking water or under-chlorinated swimming pool water and foods, such as under-cooked meat
products, unwashed vegetables and unpasteurized dairy products. STEC may also be transmitted
through petting animals [13,14]. In developed countries, STEC constitute a heightened public health
concern because of the potential for contaminated foods to be distributed on a nationwide basis.
Multi-state outbreaks in the U.S. involving contaminated beef products or vegetables highlight
this potential [15]. In 1999, the Centers for Disease Control and Prevention (CDC) estimated that
approximately 73,000 cases of hemorrhagic colitis occurred annually in the United States due to
E. coli O157:H7, with 37,000 cases caused by non-O157 serotype STEC infections [16]. Of these cases,
approximately 2000 required hospitalization, with 60–100 mortalities [16]. In 2013, the annual incidence
in the U.S. of E. coli O157:H7-associated illnesses was estimated to be 63,153 cases, while illnesses caused
by STEC serotypes other than O157 were estimated to be 112,752 cases [17]. These epidemiological
studies highlight the rapid emergence of E. coli non-O157:H7 serotypes as mediators of disease.
In 2011, a widespread outbreak of gastroenteritis occurred in Europe associated with the ingestion
of STEC-contaminated fenugreek or lentil sprouts [18]. This outbreak was particularly problematic
for two reasons: (i) the causative agent was E. coli O104:H4, a serotype previously characterized
as an enteroaggregative E. coli; and (ii) a high percentage of patients with diarrhea subsequently
developed HUS (845/3816 cases) [18,19]. The annual economic costs of E. coli O157 infections in the
United States alone, including costs of medical care, lost productivity and premature death, has been
estimated at $405 million (in 2003 dollars) [20]. Shigellosis is also a major public health problem,
especially in developing countries, with an estimated incidence of 1.1 million fatal cases per year and
annual cases worldwide estimated at 160 million [21,22]. The infectious dose of S. dysenteriae serotype
1 or STEC sufficient to cause disease in humans may be as low as 10–100 microbes [23,24]. Currently,
there are no satisfactory vaccines to prevent diseases caused by Shiga toxin-producing bacteria and no
effective therapeutic regimens to interrupt disease progression once the toxins interact with susceptible
human cells.
Shiga toxins (Stxs) are key virulence factors expressed by S. dysenteriae serotype 1 and STEC;
that is, toxin production has been shown to exacerbate intestinal damage and cause extra-intestinal
complications involving the kidneys and CNS. Many of the systemic complications seen in humans
can be reproduced by the administration of purified toxins into animals. There are two main categories
of Stxs produced by STEC, Shiga toxin type 1 (Stx1) and Shiga toxin type 2 (Stx2), based on their
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antigenic similarity to the prototypical Shiga toxin expressed by S. dysenteriae serotype 1 [25,26].
All Stxs contain a pentameric ring of identical B-subunits non-covalently associated with a single
A-subunit (see Section 2 below). The toxins cross the intestinal epithelium through processes that
may involve bacterial invasion and epithelial cell destruction (S. dysenteriae serotype 1) or transcytosis
of toxins across intestinal epithelial cells [27,28]. The toxins circulate in the bloodstream, perhaps
bound through low-affinity interactions with the surface of carrier cells, such as neutrophils or
blood monocytes [29,30]. Cellular microvesicles (MVs) [31] derived from platelets, erythrocytes and
leukocytes are detected in plasma collected from pediatric HUS patients infected with E. coli O157:H7
and adult HUS patients infected with E. coli O104:H4 [32,33]. A significant fraction of circulating
monocytes and neutrophils in HUS patients were shown to be associated with CD41+ platelet-derived
MVs [33]. Recently, Ståhl et al. [34] detected MVs derived from platelets and leukocytes containing
Stx2 in plasma of patients during the acute phase of HUS. Furthermore, Stx2-containing MVs were
also detected adjacent to or within glomerular endothelial cells in a renal cortical biopsy from
an HUS patient [34]. Taken together, these findings suggest that once in the microvasculature
serving target organs (primarily the kidneys and brain), the toxins may transfer from leukocytes or
MVs associated with leukocytes to susceptible endothelial cells via high-affinity interactions with
a membrane glycolipid receptor, globotriaosylceramide (Gb3, also known as CD77 or Pk blood group
antigen). Once bound to the receptor (Gb3), the toxins are internalized and undergo retrograde
intracellular trafficking. The receptor-mediated entry of Stxs into host cells has been extensively
studied. Gb3 cross-linking through interaction with the pentameric B-subunits is thought to trigger
receptor-mediated endocytosis [35–37]. Following internalization, the toxins are sequentially delivered
from an early endosome to the trans-Golgi network, through the Golgi apparatus, to the endoplasmic
reticulum (ER). This process is known as retrograde transport, as the toxins appear to utilize, in
a Gb3-dependent retrograde manner, the host cell machinery involved in the export of secreted or
membrane-localized proteins [38]. During transport to the ER, Stx A-subunits dissociate from the
B-subunits through a processing mechanism involving proteolysis and disulfide bond reduction [39–41].
Fragments of the A-subunits then associate with host ER intraluminal chaperones ERdj3/HEDJ,
GRP94 and BiP, followed by retrotranslocation across the ER membrane into the cytosol [42–45].
Recent studies suggest that Stxs utilize the host cell endoplasmic reticulum-associated protein
degradation (ERAD) machinery to facilitate translocation into the cytoplasm [46–48]. The ERAD
process normally targets misfolded host proteins in the ER to the proteasome for degradation. Once in
the cytoplasm, however, toxin A-fragments appear to re-fold into their active conformation [49].
This observation indicates that, as is the case for retrograde transport, the toxins may utilize normal
host cell machinery for intoxication. Delivery of the toxins to the ER and retrotranslocation of the
processed A-subunits into the cytoplasm result in host cell protein synthesis inhibition, activation of
the ribotoxic stress and ER stress responses and, in some cases, the induction of apoptosis, autophagy
and increased expression of pro-inflammatory cytokines and chemokines [50]. Remarkably, many
types of cancer cells overexpress Gb3 on their surface, and therefore, the binding of toxins or the
non-toxic pentameric Stx B-subunits coupled to anti-cancer agents has been explored for targeted
cancer therapeutics [51–54] This paper will provide a concise review of the multi-functionality of Stxs.
2. Stx Structure and Receptor Interaction
The X-ray crystal structures of Stx holotoxins, Stx1 and Stx2, at 2.5-Å and 1.8-Å resolution,
respectively, have been solved and their active sites defined from electronic densities of the
crystallization solutions (Figure 1A,B) [55,56]. All members of the Shiga toxin family share the same
structural configuration comprised of an enzymatically-active A-subunit of approximately 32 kDa
non-covalently linked with five identical B-subunits, each B-subunit protein being ~7.7 kDa in size [49].
Thus, Shiga toxins are part of a larger class of structurally-conserved bacterial protein toxins, termed
AB5 toxins, that includes Vibrio cholerae cholera toxin and the E. coli heat-labile enterotoxins [57–59].
In the crystallographic analyses of the holotoxins, the homopentameric B-subunits form a ring with
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the carboxy terminus of the A-subunit inserted within the central pore [55,56]. A major structural
difference in Stx1 and Stx2 is that in contrast to the Stx1 A-subunit, the C-terminus of the Stx2
A-subunit forms an α-helix after passing through the central pore of the B-subunits. The A-subunits
of Stxs possess a highly specific N-glycosidase activity to remove a single adenine base, located at
position 4324 in the rat, from the ribose-phosphate backbone of the 28S rRNA component of 60S
eukaryotic ribosomes [60,61]. Stx A-subunits are cleaved asymmetrically by furin or a furin-like
protease into two peptides, A1 (~27.5 kDa) and A2 (~4 kDa), that are held together by a disulfide
bond [39]. The enzymatically-active A1-fragment is released by reduction of the disulfide bond upon
exposure to the reducing conditions in the ER lumen of target cells. Mutagenesis studies showed
that the A1-fragment active site of N-glycosidase function includes position 167 (glutamic acid) [62],
which was necessary to remove an adenine base in domain VI of 28S ribosomal RNA of eukaryotic
ribosomes [60,63]. It has been reported that the B-subunits of these Stxs bind to the Gb3 receptors, while
these weakly bind to the neutral glycolipid globotetraosylceramide (Gb4) [64,65]. Recently, however,
Gallegos et al. reported that both Stx1 and Stx2 bound to Gb3 and Gb4 in vitro with comparable
affinities [66]. In human neutrophils, toll-like receptor (TLR) 4 has recently been revealed as a receptor
recognizing the A-subunits of Stxs [67]. Based on the crystal structure of B-subunits, each Stx1 and
Stx2 B-subunit monomer contains three distinct binding sites, numbered sites 1–3, for the glycan
component of Gb3 (Figure 1C,D) [68–70]. Thus, each homopentameric ring of B-subunits may contain
a total of 15 Gb3 binding sites [71]. Further , site 2 in each B-subunit demonstrated higher occupancy
than site 1, and there was less interaction detected with site 3 [72]. Based on the mutational studies
that confirmed the primary role of site 2 in Stx1 binding [73], the interaction of site 2 with Gb3 on the
target cell surface plays an essential role for the toxicity of Stx1 and Stx2 [74].
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Figure 1. Crystal structure of Shiga toxin. (A) Shiga toxin type 1 (PDB #1DM0); (B) Shiga toxin type 2
(PDB #1R4P); (C) Shiga toxin 1 B-subunit with Gb3 receptor (PDB #1BOS); (D) Shiga toxin 2 B-subunit
with Gb3 receptor (PDB #1R4P, el tion f A-subunit). In (A,B), A-subunit are shown i dark blue,
with B-subunits shown in different colors; in (C,D), individual B-subunits are shown in different
colors. PDB files of all structures were obtained from RCSB PDB (Research Collaboratory for Structural
Bioinformatics Protein Data Base, www.rcsb.org) and compiled PDB files with Chimera 1.10.2 (UCSF
Chimera, www.cgl.ucsf.edu/c i era).
The binding affinity of homopentameric B-subunits (15 binding sites, binding constant = 109 M´1) is
higher than that of monomeric B subunits (three b nding sites, binding onstant = 103 M´1), suggesting
that multiple binding sites dramatically enhance the binding affinity [75]. Most of the structural and
binding data have been collected by using Stx1. Recently, Jacobson et al. [69] reported the first crystal
structure of pentameric B-subunits of Stx2 bound to a disaccharide analog of Gb3 and demonstrated
that sites 1 and 2 are functional, and the primary binding site was site 2, as it was in experiments using
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Stx1. Interestingly, the binding affinity of carbohydrates for site 2 in Stx2 was higher than that interaction
in Stx1 [76]. Conrady et al. reported that pentameric B-subunits of Stx1 were more stable than that of
Stx2 before the crystal structure of Gb3 bound Stx2 was solved [77]. Site 3 in Stx2 B-subunits is partially
blocked by the C-terminus of the A2-fragment, leading to inactive binding sites until the A-subunit is
processed within the ER [55]. Taken together, these data may indicate that there are differences in
the receptor binding mechanisms of Stx1 and Stx2, and differences in receptor binding preferences
between Stx1 and Stx2 may contribute to different toxicities observed between the toxins [78].
Stx holotoxin molecules are internalized into the cells through clathrin-dependent or clathrin-independent
endocytosis pathways depending on the cell type examined [79]. It has been reported that the
clathrin-dependent process is the most common pathway of cellular uptake following receptor binding by
the toxins [79]. However, the full spectrum of Stx cellular uptake mechanisms remains to be characterized.
For example, Malyukova et al. [80] demonstrated that macropinocytosis is an alternative pathway for
the uptake of Stxs into cells that do not express Gb3. The unique mechanisms of internalization of
B-subunits of Shiga toxin (StxB) through Gb3 receptors, binding the pentameric form of StxB with up to
15 Gb3 receptors with high affinity [75], low immunogenicity in vivo [81] and minimization of lysosomal
degradation through the retrograde trafficking, strongly encouraged many researchers to exploit this
protein as a targeted cancer therapeutic agent, such as drug delivery and high intensity tumor cell
imaging. Indeed, StxB-based anticancer agents are currently being developed as a targeted delivery cargo
of therapeutic molecules [54,82]. Most recently, overexpression of Gb3 was detected in 57.9% of breast
cancer patients (62 of 107 patients). Interestingly, Gb3 expression is enhanced in lymph node metastases
(40% of primary tumors) and positively correlated with estrogen receptor expression, which is the most
recent clinical evidence of the expression pattern of Gb3 in cancer patients [83].
3. Stx Induces Multiple Signaling Pathways
In addition to mediating protein synthesis inhibition, Stxs are multi-functional bacterial proteins
activating a number of signaling pathways, including those associated with the activation of the
ribotoxic stress response and endoplasmic reticulum (ER) stress. Signaling through these pathways
may lead to cell death via apoptosis or autophagy or activation of innate immunity associated with
proinflammatory cytokine/chemokine production (Figure 2). Cytokine and chemokine production
may contribute to tissue damage in the colon and the development of HUS and CNS complications.
Signaling pathways activated by Stxs, linked to the eventual induction of apoptosis in epithelial,
endothelial, lymphoid and myeloid cells in vitro, may contribute to tissue damage in multiple organs.
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3.1. Ribotoxic Stress Response
As previously discussed, the binding of Stxs to Gb3 triggers toxin internalization, followed
by retrograde transport to the trans-Golgi network and ER, where processed A-subunit fragments
ultimately reach the cytosol (Figure 2). Subsequently, the N-glycosidase enzymatic activity of
Stx A1-fragments cleaves a single adenine residue from 28S rRNA of the 60S ribosomal subunit.
The depurination reaction involves an unpaired adenine residue located in a region of non-Watson-Crick
base-pairing called the α-sarcin/ricin loop (so-called because the ribosome-inactivating toxins α-sarcin
and ricin also act on the same adenine residue). This depurination process leads to loss of elongation
factor binding and inhibition of protein synthesis [57,64,84]. Following depurination, the alteration of
ribosomes by Stxs may result in the initiation of proinflammatory and proapoptotic signaling cascades
via activation of mitogen-activated protein kinases (MAPKs). This process was termed the ribotoxic
stress response after Iordanov et al. [85] showed that certain protein synthesis inhibitors, including
ricin, anisomycin and α–sarcin, mediating site-specific modifications to the ribosomal peptidyl
transferase center, activated c-Jun N-terminal kinase 1 (JNK1). Thus, the work of Iordanov et al. [85]
suggested that Stxs should activate stress-activated protein kinase cascades, as well. However, other
molecules, such as cycloheximide, emetine, T-2 toxin, pactamycin and puromycin, capable of effectively
inhibiting protein synthesis, failed to induce the ribotoxic stress response through activation of JNK1.
Thus, eukaryotic ribosomes possess a selective stress sensory function leading to the activation
of cell stress responses. It was subsequently shown using human epithelial and monocytic cell
lines that Stx-mediated modification of the ribosome triggered not only the activation of the c-Jun
N-terminal kinases (JNKs), but also activated the p38 mitogen-activated protein kinase (p38 MAPK) and
extracellular-signaling regulated kinase (ERK) pathways [86–88]. These studies supported the necessity
of Stx A1-fragment retrotranslocation and action on the ribosomal peptidyl transferase center for MAPK
activation. The complete signaling cascades linking alterations in ribosomal function with MAPK
activation remain to be fully characterized (Figure 2). However, the upstream kinase, double-stranded
RNA-activated protein kinase R (PKR; a serine/threonine kinase) activated by damaged ribosomes
through interaction with two dsRNA-binding domains has been identified as a mediator of the ribotoxic
stress response [89]. Zhou et al. showed that PKR participates in signaling during the ribotoxic
stress response induced by ribosome-inactivating proteins ricin, Stxs or the fungal trichothecene
toxin deoxynivalenol (DON) [90]. Moreover, IL-8 expression induced by DON through the ribotoxic
stress response required a second kinase, hematopoietic cell kinase (Hck), which associates with the
40S ribosomal subunit and triggers activation of ASK1, MKK3/6 and p38 MAPK in mononuclear
phagocytes [91]. The observation on the requirement to generate a scaffold for the direct binding of JNK
and p38MAPK to double-stranded RNA binding protein E3L suggests that PKR is an immediate sensor of
ribosomal alterations [92]. Jandhyala et al. [93] have shown that the MAP3K zipper sterile-α-motif kinase
(ZAK) is involved in the ribotoxic stress response. A ZAK inhibitor and ZAK siRNAs blocked Stx2- and
ricin-mediated activation of stress-activated protein kinases and partially protected Hct8 and Vero cells
from Stx2-induced apoptosis. In contrast to these intestinal and renal epithelial cell lines, the Ramos
Burkitt’s lymphoma cell line appears to express basal levels of activated p38 MAPK, and Stx1 treatment
did not increase p38 MAPK activation above basal levels. Inhibitors of p38 MAPKs actually increased
apoptosis induced by Stx1 treatment of Burkitt’s lymphoma cells [94]. Taken together, these data suggest
that there may be multiple signaling pathways for the activation of the ribotoxic stress response, some of
which may be cell-type specific. The complete characterization of upstream regulators involved in the
ribotoxic stress response elicited by Stxs may be required to develop effective interventional therapeutic
approaches to prevent the progression of disease caused by the toxins.
3.2. ER Stress
The ER is a multifunctional organelle, where, following synthesis by ribosomes, nascent
polypeptides are folded correctly and the proteins transported to other parts of the cells or secreted.
The ER is also critical in regulating intracellular calcium levels. However, overloading the ER
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lumen with truncated or misfolded proteins leads to ER stress and initiation of the unfolded protein
response (UPR) to cope with the stress [95–97]. If activation of the UPR fails to clear the cause of ER
stress, apoptotic cell death may follow (reviewed by Szegezdi et al. [98]). The chaperone binding
immunoglobulin protein (BiP, also known as GRP78) is typically associated with the following three ER
membrane proteins to sense the levels of unfolded proteins: RNA-dependent protein kinase-like ER
kinase (PERK), inositol-requiring ER to nucleus signal kinase-1 (IRE1) and activating transcription
factor-6 (ATF6). In host-pathogen interface studies, the ER stress response has been reported to be
activated, and the subsequent triggering of the UPR may contribute to a cytoprotective response
directed against invading microorganisms, including various viruses or bacteria [99–102]. Of note,
Stx molecules are thought to associate with ER-resident chaperone proteins HEDj/ERdj3, Grp94 and
BiP, suggesting that during retrotranslocation, Stx A1-fragments may exist in a transient unfolded
state [43,44]. Using monocytic THP-1 cells, Lee et al. [103] first demonstrated that Stx1 was capable of
inducing ER stress and activating the three proximal UPR effectors, PERK, IRE1 and ATF6, involved in
the immediate detection of unfolded proteins (Figure 2). In addition to monocytic cells, ER stress
signaling activated by Stxs has been investigated in other cell types. Using the immortalized human
proximal tubule epithelial cell line HK-2 as an in vitro model of Stx-mediated renal damage, Stx1
and Stx2 were shown to differentially activate non-overlapping sensors of ER stress. The intoxicated
cells were susceptible to the cytotoxic action of Stxs with significant cleavage of poly(ADP-ribose)
polymerase (PARP), an enzyme primarily involved in DNA repair and induction of programmed
cell death [104]. Parello et al. observed that prolonged renal ER stress was capable of contributing
to apoptosis in murine models of Stx2-induced kidney injury, although the downregulation of ER
stress induced by Stx2 was not sufficient to prevent renal cytotoxicity in mice [105]. When Caco-2 cells,
a cultured line of human enterocytes, were exposed to Stx2, autophagic cell death preceding apoptosis
was promoted through ER stress [106]. The precise relationships of ER-to-cytoplasm retrotranslocation
processes in inducing ER stress and apoptosis in cells maintained in vitro vs. Stx-induced organ injury
leading to organ failure in vivo remain to be fully characterized. However, Stx trafficking to the ER and
transport of processed toxin across the ER membrane are critical steps in toxin-mediated cell death,
and additional investigations are needed to define reasonable therapeutic targets in toxin trafficking
pathways to intervene in disease progression.
3.3. Apoptosis
Apoptosis (programmed cell death) is a form of cell death that ensues following activation
of intracellular signaling pathways in response to a variety of cell stressors. The ability of Stxs to
induce apoptosis may play an important role in causing intestinal damage, as well as extra intestinal
complications, such as HUS and vascular damage in the CNS. For example, in HUS, extensive damage
to glomeruli and renal tubular epithelial cells was observed with pyknotic nuclei and sloughing of cells
into the tubule lumina [107]. Cellular apoptotic characteristics, including cytoplasmic condensation,
nuclear chromatin changes, formation of apoptotic bodies and DNA fragmentation, were observed
in Vero cells treated with Stx1 by utilizing light microscopy and DNA-agarose gel electrophoresis
with ethidium bromide staining [108]. Moreover, apoptotic nuclei localized to tubular epithelial cells
and glomerular cells were observed after TUNEL staining of renal cortical tissues [109]. Using renal
biopsies from seven HUS patients, te Loo et al. [110] subjected the tissue samples to dual staining
with TUNEL and SC-35 (a dye to label for RNA synthesis and splicing factor to avoid non-specific
TUNEL positive staining) and showed that 80% of apoptotic cells were detected in tubules and 20%
in glomeruli. Smith et al. [88] linked the apoptotic programmed cell death pathway with signaling
through the ribotoxic stress response triggered by exposure to Stx1 in the human epithelial cell line
Hct8. Functionally-active Stx1 holotoxin, but not an enzymatically inactivated Stx1 mutant, triggered
caspase-3 (executioner caspase) activation and nuclear fragmentation (karyorrhexis). Hct8 cells were
partially protected from apoptosis with reduced activity of caspase-3 and DNA fragmentation when the
cells were stimulated with a p38 MAPK inhibitor prior to treatment with Stx1 [88]. In Hct8 and Vero cells,
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DHP-2, a pharmacological inhibitor of the upstream MAP3K ZAK, blocked Stx2-mediated activation of
JNK and p38MAPK, partially protected cells from apoptosis and partially reduced caspase-3 activation
without altering protein synthesis inhibition caused by the toxin [93]. Thus, ZAK appears to specifically
link signals generated by Stxs with stress-activated protein kinases and apoptosis.
Using human macrophage-like cells in various stages of maturation, the anti-apoptotic factor
Bcl-2 was shown to be a crucial mediator of apoptosis or cell survival following Stx intoxication.
Enhanced protein and mRNA expression of Bcl-2 were associated with protection from apoptosis
induced by Stx1 in toxin-resistant macrophage-like cells under ER stress, while Bcl-2 expression was
decreased in toxin-sensitive monocytic cells, leading to rapid apoptosis in the presence of the toxin [111].
Furthermore, amino acid Ser70 of Bcl-2 was phosphorylated, and the protein failed to translocate to
mitochondria following Stx1 treatment of macrophage-like cells. In contrast, the phosphorylation
of Bcl-2 at Ser70 was significantly reduced in toxin-treated monocytic cells [111]. The full or potent
anti-apoptotic function of Bcl-2 requires JNK-mediated phosphorylation of Bcl-2 at Ser70 [112,113].
Thus, Bcl-2, a critical regulator controlling the onset of apoptosis in response to Stx1, was differentially
phosphorylated by intoxication. These data suggest that the activation of MAPKs via the ribotoxic
stress response may “cross-talk” with the UPR induced by Stxs to regulate Bcl-2 protein expression
and activation, which may, in turn, ultimately control apoptosis or cell survival. Although mature
macrophage-like THP-1 cells are relatively resistant to the rapid induction of apoptosis by Stxs,
downstream signaling through the apoptosis-inducing receptor-ligand pair DR5-TRAIL during ER
stress contributes to delayed apoptosis detected in Stx1-treated macrophage-like THP-1 cells [114].
Although apoptotic signaling by Stxs has been observed in many different cell types, there remains
much uncertainty about the precise mechanisms by which Stxs activate apoptosis. Ikeda et al. [115]
found increased intracellular calcium levels and prolonged activation of p38MAPK when Vero
cells were treated with Stx1 or Stx2. In this study, treatments with inhibitors of Ca2+-mediated
signaling (BAPTA-AM, calcium chelator) and inhibitors of p38MAPK partially protected the cells from
intoxication. Treatment of the laryngeal epithelial cell line HEp-2 with Stx1 and Stx2 increased
the expression of the pro-apoptotic protein Bax without altering the level of pro-apoptotic Bak
and anti-apoptotic Bcl-2 expression [116]. Moreover, overexpression of the pro-survival protein
Bcl-2 protected the cells from Stx2-induced apoptosis. Using confocal fluorescence microscopy with
fluorescein isothiocyanate-conjugated anti-Bax antibody and MitoTracker Red, Lee et al. observed
that Stx1 was involved in triggering mitochondrial translocation of the pro-apoptotic Bcl-2 family
protein Bax [111]. Stx-induced apoptosis in the HeLa cell line (cervical adenocarcinoma cells) was
extensively characterized by Fujii et al. [117]. They found that apoptosis induction required toxin
enzymatic activity and was characterized by activation of caspases-3, -6, -8 and -9. Peptide-mediated
inhibition of caspases-3, -6 and -8 blocked apoptosis. In human dermal microvascular and pulmonary
arterial endothelial cells, proteasome-mediated degradation of anti-apoptotic Bcl-2 family member
Mcl-1 preceded apoptosis (as measured by caspase-3 activation) induced by Stx1 and Stx2, suggesting
a crucial role for Mcl-1 in apoptotic signaling in toxin-treated endothelial cells [118]. A different
mechanism of signaling in Stx1-induced apoptosis was observed using Burkitt’s lymphoma (BL)
cells. BL cells are thought to represent transformed counterparts of normal centroblasts and display
high expression of the B-cell differentiation antigen CD77 (Gb3). Stimulation of Ramos BL cells with
Stx1 resulted in rapid apoptosis with 50% reduction in viability within 9 h [119]. Rapid cleavage
of pro-caspase-8, beginning 2–4 h after toxin exposure, was reported to occur coincident with
the degradation of c-FLIPL in Stx1-treated BL cells [94]. Apoptosis was not only induced when
BL cells were incubated with Stx holotoxin, but was also induced when BL cells were exposed
to recombinant toxin B-subunits or immobilized anti-Gb3/CD77 monoclonal antibody, thereby
dissociating an apoptotic pathway induced by toxin enzymatic activity from a pathway induced
by Gb3 cross-linking [120,121].
Less is known about the apoptosis signaling mechanisms activated by Stxs in vivo. Apoptotic death
was noted in renal tubular cells on biopsy specimens obtained from a child with Stx-mediated
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HUS [122], and renal biopsies from HUS patients infected with STEC revealed extensive damage to
glomeruli with evidence of apoptotic changes and DNA fragmentation [123]. In the mouse model
of Stx-mediated renal damage, Stx2 targeted murine collecting duct epithelium with evidence of
toxin-induced loss of function contributing to renal failure through the induction of apoptosis in
Gb3+ murine renal cortical and medullary tubular cells [124]. Recently, in order to monitor HUS
disease progression utilizing a system more closely resembling the human kidney, DesRochers et al. [125]
investigated the effect of Stx2 on a bioengineered three-dimensional model of human renal tissue.
They observed similar aspects of cytotoxicity following toxin exposure as had been described
in two-dimensional cell culture [125]. Numbers of apoptotic monocytes and neutrophils were
significantly elevated in the circulation of HUS patients, and leukocyte cell death positively correlated
with disease severity as monitored by admission to the intensive care unit [33]. The precise location
of Gb3 in the mouse and human CNS is controversial, and unlike Stx-mediated renal programmed
cell death, apoptotic neuropathogenesis induced by Stxs has not been extensively examined,
although rabbit neurons appear to be susceptible to Stx-induced apoptosis [126]. The identification
of intermediate signaling molecules in Stx-induced apoptosis may represent therapeutic targets
to intervene in toxin-induced cell death, thereby ameliorating tissue damage caused by Stxs [127].
However, many details on apoptotic signaling pathways initiated by Stxs remain to be clarified.
3.4. Autophagy
Autophagy is a catabolic process originally defined as providing survival signals for cells
undergoing nutrient deprivation. During autophagy, a double membrane forms around damaged
organelles or intracellular substrates to generate an autophagosome. This double-membraned vesicle
may then fuse with late endosomes or lysosomes to mediate the degradation of the inner membrane and
autophagosomal contents. However, it is now understood that depending on the cell type and the type of
stress encountered, autophagy may antagonize or facilitate apoptosis or necrosis [128–131]. For example,
while nutrient deprivation leads to autophagy, the removal of damaged organelles and cell survival, if
cellular homeostasis is not restored, then delayed apoptosis may follow. Booth et al. [132] suggested that
there is regulation of apoptosis by autophagic protein partners and vice versa by “cross-talk” between
the two pathways. Based on the observation that treatment of MDCK or Vero cells with autophagy
inhibitors, such as 3-MA, protected cells from apoptosis induced by the ribosomal-inactivating proteins
Stx and ricin, autophagy signaling may be necessary for Stxs to induce cell lysis in toxin-sensitive
cells [133]. While more work remains to be done to fully elucidate the direct effects of Stxs on
autophagy, it is now known that Stx-induced signaling pathways leading to the induction of autophagy
may activate apoptosis or cell survival programs conferring the toxin-sensitive or toxin-resistant
phenotypes, respectively [134] (Figure 2). Lee et al. [134] observed that in toxin-resistant primary
human macrophages, Stxs are translocated to lysosomes, and autophagy is induced in the absence of
calpain and caspase activation, as well as Atg5 and Beclin-1 cleavage. In contrast, using toxin-sensitive
cells, Stxs are translocated to the ER; the ER stress response is activated; and autophagy is induced
in association with the activation of calpains and caspase-8 and-3, as well as the cleavage of Atg5
and Beclin-1. Recent studies support a role for autophagic signaling in Stx-mediated cytotoxicity.
Tang et al. [106] showed that treatment of intestinal epithelial cells with Stx2 initiated autophagic cell
death via the ER stress pathway and by triggering pseudokinase TRIB3-mediated DDIT3 expression
and AKT1 dephosphorylation. It is interesting to note that in contrast to studies supporting a role for
autophagy in cell death, autophagy may attenuate ER stress through the sequestration and degradation
of unfolded proteins [130,135,136]. Given that autophagy may coincide with apoptosis and promote
cell death, or antagonize apoptosis to promote cell survival, further studies are warranted to elucidate
precise mechanisms by which autophagy induced by Stxs facilitates or inhibits apoptosis.
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3.5. Inflammatory Response
The depurination of the ribosome by the enzymatic A1-fragment of Stxs is a crucial event in the
activation of host signal transduction pathways leading to the proinflammatory response [87,137–139].
Inflammatory responses include, in part, the synthesis and secretion of cytokines and chemokines
by immune cells following the detection of “danger signals”, such as bacterial cell membrane or cell
wall components, toxins or flagellins [140,141]. The regulated elicitation of inflammation leads to the
elimination of microbes or foreign agents. However, excess inflammation may lead to harmful effects,
including septic shock, organ failure or tissue damage [142,143]. Multiple studies have suggested that
the innate immune response is activated by Stxs, which, in turn, play a role in disease progression
and/or tissue injury by inducing the increased expression of genes involved in the biosynthesis of
the toxin-binding glycolipid Gb3. Thus, the production of pro-inflammatory cytokines in response to
the toxins may sensitize microvascular endothelial cells found in target organs to the cytotoxic action
of Stxs [144–146]. In 1995, Raqib et al. [147] measured proinflammatory cytokine levels in plasma
and stool obtained from patients infected with S. dysenteriae serotype 1 or non-toxigenic S. flexneri.
Levels of cytokines detected in stool were approximately 100-times higher in stool than plasma at
the onset of diarrhea. Furthermore, they observed that levels of the pro-inflammatory mediators
TNF-α, IL-8, IL-1β, IL-6 and GM-CSF directed into the stool were significantly higher in patients
infected with Stx-producing S. dysenteriae serotype 1 than in patients infected with S. flexneri. In sera
from HUS patients infected with E. coli O157:H7, levels of IL-6, IL-8, IL-10 and endothelin were
significantly elevated compared to those patients infected with E. coli O157:H7 experiencing colitis
only [148]. The cellular sources of the elevated cytokines detected in the circulation of HUS patients
are not known. Several studies support the concept that macrophages may be the source of cytokine
production to promote tissue damage through increased toxin receptor expression and/or leukocyte
recruitment. When monocytic THP-1 cells were differentiated into the macrophage-like state, the
cells became relatively resistant to the cytotoxic action of Stxs, but also became capable of secretion
of TNF-α, IL-1β, IL-8, MIP-1α, MIP-1β, MCP1 and Groβ [138–140]. Stx-induced cytokine expression
was manifested in the presence or absence of lipopolysaccharide (LPS) [87,139,149–151]. Furthermore,
non-adherent primary human monocytes cultured in Teflon foil bags were found to respond to Stx1
or Stx2 by producing TNF-α and GM-CSF without undergoing apoptosis, suggesting that peripheral
blood monocytes may be a cellular source of the cytokines in the circulation [152]. Several studies have
reported that despite expressing toxin receptor Gb3, human monocytes/macrophages are relatively
insensitive to the cytotoxic action of Stxs compared to other Gb3+ cell types, which are highly
toxin-sensitive [134,153,154]. Monocyte insensitivity to Stxs appears to correlate with the failure of Gb3
to associate within lipid rafts, which may be necessary for efficient retrograde transport of Stxs [155].
Taken together, these data suggest that infiltrating macrophages may produce tissue factors and
cytokines in response to Stxs that further augment inflammation, thrombogenesis and tissue damage
to ultimately lead to organ failure [156]. Multiprotein complex inflammasome function in Stxs-induced
inflammatory cytokine expression and its role in host cell death have been incompletely understood.
Very recently, Lee et al. have reported that Stxs induce NLRP3 inflammasome activity, resulting in
cleaved caspase-1 to release active proinflammatory cytokine IL-1β and promoting apoptotic cell death
by increasing caspase-3 activity [157].
Evidence for energy-requiring transcytotic and/or paracellular Stx1 and Stx2 epithelial transport
systems has been presented [158]. The innate immune response may facilitate the chemotactic
infiltration of inflammatory cells into the lamina propria of the gut and, thus, mediate cell morphology
changes in the intestinal epithelial barrier, which allow Stxs to cross into lamina propria to damage
colonic blood vessels to initiate hematogenous spread [28]. In intestinal cell lines T84 and HCT-8, it
has been demonstrated that Stxs play a role as mediators of intestinal inflammation for the induction
of IL-8 protein and cytokines in response to the toxin may facilitate intestinal colonization [159,160].
It has become increasingly apparent that Stxs as multifunctional signaling molecules activate cell
stress responses and may contribute to the toxin-induced inflammation, in addition to the capacity of
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the toxin to mediate adenine depurination from the rRNA backbone. Stx activation of MAP3K ZAK
through the ribotoxic stress response results in activation of MAP2Ks that subsequently phosphorylate
MAPK JNK and p38 along with activation of ERK1/2 via phosphorylation of MEK1/2 in promoting
intestinal epithelial inflammation by inducing IL-8 mRNA expression [160]. Of note, the initiation of
intestinal inflammation in hemorrhagic colitis during the infection with Shiga toxin-producing bacteria
is multifactorial, with other microbial products participating in the induction. For example, Miyamoto
et al. treated human intestinal epithelial Caco-2 cells with purified H7 flagellin in the presence or
absence of Stx2 and showed that flagellin signaling through TLR5 may be a relatively more potent
inducer of IL-8 production in an in vitro model system [161].
Following the entry of Stxs across the intestinal epithelial barrier into the bloodstream,
a primary target organ for vascular damage and failure is the kidney. Using a murine model of
Stx-mediated renal damage, macrophages were recruited to the kidneys of mice challenged with
Stx2, and elevated levels of chemoattractants, such as MIP-1α, were detected in the kidneys [162].
Using a non-human primate model of HUS, after intravenous injections with Stxs, the baboons
developed progressive thrombocytopenia, HUS with signs of glomerular thrombotic microangiopathy
and systemic inflammatory responses in the baboon kidney, small intestine, colon, lung and spleen,
with striking chemotactic profiling of highly expressed mRNAs for IL-8, MCP-1 and MIP-1α [163,164].
The regulation of cytokine and chemokine expression by Stx-treated macrophages appears to be quite
complex. In addition to activating MAPK cascades, Cherla et al. [165] demonstrated that signaling
through the PI3K/Akt/mTOR pathway initially activated cytokine expression via the phosphorylation
of the eukaryotic translation initiation factor 4E-BP, but then negatively regulated proinflammatory
cytokine production through the phosphorylation (inactivation) of the positive regulator of cytokine
production, glycogen synthetase kinase (GSK)-3. These data suggest that embedded within the
Stx-induced signaling mechanisms enhancing cytokine production are signals that will ultimately
down-regulate cytokine production and return the host to a normal homeostatic state. In addition
to the tight regulation of the proinflammatory response, the timing of exposure to Stx1 or Stx2 vs.
cytokine production has been shown to be critical in the outcome of disease in vivo. Mice receiving
TNF-α for 1 h prior to toxin exposure were protected from lethality, while mice receiving TNF-α
after the administration of toxins displayed increased lethality associated with increased glomerular
damage [166]. Using immortalized adult human proximal renal tubular epithelial cells, HK2, treatment
with Stx2 selectively produced two chemokines MIP-1α (CCL3) and MIP-1β (CCL4) that were not
induced by Stx1 treatment [104]. Although Stxs are primary pathogenic virulence factors for HUS
development, in severe cases of HUS, the toxin-mediated damage is not limited to the kidney, but
may extend to the brain as another important target for the toxin after entering systemic circulation.
In human brain microvascular endothelial cells (HBMEC) and human brain endothelial cells (HBEC),
pretreatment with TNF-α and IL-1β as inflammatory stimuli markedly increased the toxicity of Stxs by
enhancing the expression of the toxin receptor Gb3 on these cells in comparison with the untreated cells,
suggesting the role of proinflammatory cytokines in sensitizing brain cells to the toxins [145,146,167].
In the 2011 outbreaks of Shiga toxin-producing EHEC infections in Germany, these findings were
confirmed in the brain of infected patients with HUS and neurological complications as a consequence
of systemic inflammatory cascades activated by upregulating CD77/Gb3 neuronal expression [168].
Importantly, a rabbit model treated with purified Stx2 showed that neuroinflammatory responses, such
as increased expression of TNF-α or IL-1β in the CNS parenchyma and microglial activation at an early
stage, may lead to occasional apoptotic neurons as the onset of neurological symptoms later in the
disease [126]. The unanswered question regarding the precise mechanism of Stx-mediated neurological
damage highlights the importance of inflammatory mediators or the permeability of brain endothelial
cells to influence blood-brain barrier (BBB) function once Stxs reach brain parenchyma. Landoni et al.
demonstrated that Stx1-induced secretion of TNF-α on LPS-stimulated astrocytes, inflammatory cells
in the brain, affected the integrity of brain endothelial cells and maintenance of BBB properties to
contribute to the development of neuropathological symptoms observed in HUS [169].
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Histologic examination of animals revealed that monkeys receiving the toxin-producing strains
had damage to colonic capillaries within the lamina propria and inflammatory vasculitis of peritoneal
mesothelium. Thus, the production of Stx was associated with increased vascular endothelium damage.
We and others showed that human endothelial cells derived from a number of anatomical sites became
more sensitive toward Stx cytotoxicity when they were simultaneously treated with the toxins and
proinflammatory cytokines TNF-α or IL-1β [145,170,171]. Van de Kar et al. showed that pre-exposure
of endothelial cells to both TNF-α and IL-1β upregulated the expression of membrane Gb3 on the cells
in vitro [144]. However, endothelial cells in vitro appeared to be relatively refractory to the cytotoxic
action of Stxs [145]. We also showed that the administration of a single dose of murine TNF-α
after Stxs administration in mice dramatically affected renal pathology, so that glomeruli showed
increased vascular damage [166]. Collectively, these data suggest that the innate immune response
elicited by Stxs contributes to the development of vascular lesions by sensitizing endothelial cells
to the action of the toxins. Further understanding of how Stxs regulate the expression of pro- and
anti-inflammatory effectors, as well as the cytokine and chemokine profiles expressed by specific cell
types will be necessary to develop therapeutic agents to ameliorate tissue damage. More information
on the signaling mechanisms activated by Stxs to modulate the inflammatory response can be found in
the review of Lee et al. [172].
4. Toxin Engineering for Therapeutics
The use of engineered toxins as cancer therapeutic agents represents one of the most novel
approaches in targeted cancer therapy. Stxs are promising candidates in this approach because
the toxins have several intracellular processing steps necessary to express toxicity. Thus, host cell
targeting factors may be used to activate the engineered Stx molecule (inactivate toxicity or activate
the anti-cancer agent). For example, the introduction of a tumor protease binding site in the A-subunit
in place of the furin cleavage site would biologically “switch-off” Stx toxicity without affecting
B-subunit binding and retrograde transport, delivering the engineered molecule to its intracellular
target. Many tumor cells overexpress Gb3 on their surface, including tumors of the colon [52,173,174]
and breast [175]. It was recently reported that Gb3 expression was detected in 17 out of 25 tumors from
breast cancer patients [176] and from glioma cells [177]. Intratumoral injection of Stx1 inhibited tumor
growth in mouse xenograft models, clearly demonstrating an antineoplastic effect [178]. Stx1 has
been applied to several types of tumors, such as fibrosarcoma [53], meningiomas [179] and bladder
carcinoma [178]. Xenografts of human renal carcinoma completely regressed with a single intratumoral
injection of Stx1 [180], and apoptosis was detected without other side effects in this model [181].
These findings strongly suggest that Stxs could be exploited to target human cancers. However, there
are side-effects to overcome using Stxs as targeted cancer therapeutic agents, such as microvascular
damage and, in the worst case, the development of HUS or CNS abnormalities.
Non-toxic B-subunits of Stxs may be developed to target cancer cells. Stx B-subunits would, in
principal, deliver therapeutic agents into cancer cells. There are several on-going trials to engineer
Stxs for cancer targeting and drug delivery, especially in the area of cancer cell detection by using
the Gb3 receptor and B-subunits labeled with positron emitters [51]. The B-subunits of Stxs have
many of the desired molecular characteristics for the delivery of cargo molecules to intracellular
sites. These characteristics include stability across a broad pH range, resistance to proteases and the
capability of crossing tissue barriers [81]. Janssen et al. reported that Stx B subunits conjugated to
contrast agents targeted Gb3-expressing adenocarcinomas in a transgenic mouse model using different
imaging modalities [51] (see the excellent review summarizing Gb3 expression levels in primary
human cancers [82]). Stx B-subunit and photosensitizer (TPPp-O-β-GluOH)3 conjugates killed cancer
cells [182]. A seminal study utilizing this approach involved the creation of a B subunit-camptothecin
11 (topoisomerase I inhibitor) conjugate linked by a disulfide bond. This agent was highly cytotoxic
for HT29 colorectal carcinoma cells in vitro [183]. The most interesting concept explored in this study
was to design the conjugate so that the anti-cancer drug was released in the ER after reduction
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of the disulfide linkage connecting the Stx B subunits with camptothecin 11 [183]. This approach
represents an advanced drug payload technique, which may be used in conjunction with antibody-drug
conjugates (ADC). Batisse et al. reported the successful construction of Stx B subunit-monomethyl
auristatin (MMA)/monomethyl auristatin E (MMAE) conjugates that released MMA/MMAE upon
reaching the reducing environment in the ER [184] (Figure 3). These conjugates have the potential
to eliminate tumor cells overexpressing Gb3 on their surface [184]. Likewise, StxB conjugation with
contrast agents has the potential to be used for targeted tumor imaging. Fluorophore-labeled StxB
was accumulated and detected in digestive cancers in vivo after 2.5 h of oral administration. Further,
StxB-[18F] fluoropyridine-StxB conjugates that were systemically injected significantly improve the
efficiency of PET imaging toward digestive tumors in mouse [51]. Viel et al. reported that fluorescent
StxB conjugates were accumulated around the tumor area and enter the Gb3-expressing cancer cells in
xenografted nude mice. In addition, they demonstrated a potential of these conjugates for the analyses
of tumor at the cellular level with confocal microscopy [185]. Further, the targeted imaging of cancer
cells by StxB-functionalized fluorescent microbubbles (micro-sized gas bubbles as ultrasound contrast
agents [186]) has been demonstrated. These StxB microbubbles significantly enhanced the intensity
of ultrasound imaging in vitro and in a tumor xenograft mice model [187]. Based on these findings,
StxB-based targeted imaging agents might be a novel diagnosis method for cancer patients in early stages.
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In developing personalized cancer therapies, the stability of the therapeutic agents and their
targeting specificity still remain as challe es. Despite recent advance i drug delivery technology,
non-specifi delivery a d low efficacy of the agents must be avoid d. To enhance specific ty, agents
need to be engi eered with multi-targeting factors, because non-cancerous cells may also have “tumor
targeting recept rs” n their surface. In order to achieve this goal by protein e g neering, toxins requ ring
multiple steps for intoxication of target cells have an advantage. Naturally-occurring toxins may require
many host cell-specific targeting factors to reach intra ellular sites of action. One can engineer these
toxins to carry cancer-specific molecules, such as tumor proteases or tumor-specific receptors. Stxs are
excellent candidates for anti-cancer drug delivery, because they hav at least three well-defined
processing steps involved in intoxication that may be manipulated: Gb3 binding, proteolysis y furin
a d reduction f a disulfi e b nd. Future studi s exploring the utility of S xs engineered molecules
for drug delivery may include alterati n of the Gb3 b d ng sites defined on B-subunits t specifically
bind receptors uniquely displayed on cancer cells. The alteration of the A-subunit furin binding
domain to a tumor protease binding domain would enhance targeting specificity. Reduction of the
disulfide bond could potentially release the anti-cancer agent once inside the target cells.
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5. Conclusions
Infections with Shiga toxin-producing bacteria continue to be a significant world-wide public
health concern. Advances in clinical treatment have primarily been limited to supportive therapies,
and prevention has focused on improved education of the public on the risks of ingesting contaminated
food or water. Shiga-toxin producing bacteria are still a significant cause of morbidity and mortality,
and the development of vaccines and effective interventional therapies is clearly needed. Shiga toxins
comprise a family of genetically- and functionally-conserved cytotoxins produced by the enteric
pathogens Shigella dysenteriae serotype 1 and an increasingly expanding group of Escherichia coli
serotypes [188]. The purification and subsequent elucidation of the crystal structures of the Stxs were
critical in formulating structure/function studies defining toxin binding, intracellular routing and
processing and the mode of action [188]. It has become increasingly apparent that while Stxs are potent
protein synthesis inhibitors, they are also multifunctional proteins capable of activating signaling
pathways initiated by the ribotoxic stress response and ER stress, leading to apoptosis, autophagy
and/or cytokine/chemokine production. Stx-induced signaling pathways may contribute to damage
in the colon and the development of life-threatening conditions, such as acute renal failure (HUS) or
neurological disorders. Studies to identify key signaling molecules most necessary for promoting
damage to the host are needed. Since the ribotoxic stress response and ER stress elicited by Stxs have the
ability to activate apoptosis, autophagy or proinflammatory cytokine/chemokine production, blocking
the proximal sensors of stress or their downstream effector molecules potentially represent therapeutic
approaches to treat illnesses caused by Stxs. However, Stxs may induce different signaling pathways
in different cell types, which may contribute to cell death or cell survival. An improved understanding
of intermediate signaling molecules involved in influencing both Stx-mediated toxicity and pathogenic
effects may provide researchers with potential targets to intervene in toxin-induced disease progression.
Further, engineering Stxs may be a promising approach to develop novel anticancer therapeutics with
high targeting specificity and therapeutic efficacy.
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